Glenmark launches Adapalene Gel pump packs in US to tap $45.8m market
- Glenmark Therapeutics Inc. USA launched Adapalene Gel USP 0.1% in pump packs on October 6, 2026
- The launch targets a $45.8 million annual market segment in the United States
- Product serves as therapeutic equivalent to Differin® Gel active ingredient
*this image is generated using AI for illustrative purposes only.
Glenmark Pharmaceuticals subsidiary Glenmark Therapeutics Inc. USA launched Adapalene Gel USP, 0.1% (OTC) in new pump packs on October 6, 2026. The move targets a $45.8 million annual market segment in the United States.
The newly launched product serves as a therapeutic equivalent to the active ingredient found in Differin® Gel, 0.1%. This launch expands the company's consumer health portfolio by offering a convenient dispensing option for over-the-counter dermatology treatments.
Market opportunity and product positioning
According to Nielsen syndicated data for the 52-week period ending September 5, 2026, the market for Differin® Gel, 0.1% (OTC) achieved annual sales of approximately $45.8 million. The market definition includes the brand and all available therapeutic equivalents.
The product is marketed exclusively for indications listed in Glenmark’s approved drug facts label. It is important to note that this product is not manufactured or distributed by Galderma Laboratories, L.P., the owner of the Differin® trademark.
Strategic focus on North America
Marc Kikuchi, President and Business Head for North America, stated that the introduction of the pump pack enhances consumer experience through ease of use. He noted that the launch strengthens the growing U.S. dermatology portfolio and reflects a commitment to delivering high-quality, affordable healthcare solutions.
What the numbers show
The launch enters a competitive landscape where the reference brand and its equivalents collectively generate $45.8 million annually. By introducing a pump-pack variant, Glenmark aims to differentiate its offering from traditional tube formats within this established revenue pool, leveraging convenience as a key differentiator in the OTC dermatology sector.
Historical Stock Returns for Glenmark Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -1.32% | -5.83% | +9.71% | +15.90% | +341.52% |
How might the pump-pack format influence market share capture rates compared to traditional tube-based competitors in the first year?
What impact will this launch have on Glenmark's overall North American consumer health revenue projections for fiscal 2027?
Are there indications that Galderma or other major dermatology players plan to introduce competing pump-pack formats to defend their Differin market share?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
